Complix has generated pre-clinical proof of concept data which demonstrate that CPABs can penetrate cancer cells and act on intracellular targets to induce a therapeutic effect.
Proof of concept data were produced with Mcl-1 as the target. Mcl-1 is an important regulator of cellular apoptosis, determining whether a cell survives or dies. The MCL-1 locus is one of the top 10 most amplified genomic regions in cancer, with increased expression/activity in a variety of cancers. Its overexpression prevents tumor cells from entering into the apoptosis phase and dying.
Anti-Mcl-1 CPABs were designed to block Mcl-1 therefore driving tumor cell death. In vitro and in vivo data showed that the CPABs are specifically acting on their target and that they effectively inhibit tumor growth.
Recent studies have also demonstrated that Complix can design and create CPABs that penetrate the nucleus of cancer cells. In December 2017, the Company received a grant from VLAIO to further expand its pipeline of proprietary CPABs against intracellular cancer targets based on the design of nucleus targeting CPABs.
Work to-date has shown that CPABs, which are specific for selected cancer targets, are active in a variety of tumor cells and are well-tolerated by normal human cells.